A comprehensive study has been carried out of the effect of long-term oral D-penicillamine treatment of a group of 15 patients with severe chronic rheumatoid arthritis. This has involved a monthly clinical assessment as well as measurement of various blood and serum protein parameters. Of the latter, changes in serum C-reactive protein and haptoglobin levels mirrored most closely the clinical improvement seen in all but one of the patients. Striking changes in serum IgG, IgM and IgA levels were, in general, not observed; but whilst the serum IgA concentration of 5 patients remained abnormally high, another patient became completely deficient in this immunoglobulin. A sharp rise in serum IgE level was observed in 14 out of the 15 patients examined soon after commencement of penicillamine therapy, this being succeeded in more than half of the patients by a gradual but significant decrease in this immunoglobulin. The effect on circulating antibody levels was variable; although rheumatoid factoi and anti Gm titres tended to fall following penicillamine treatment, whereas ANF titres tended to rise. In contrast, the serum isoagglutinin levels remained constant throughout the course of treatment.
Oral treatment with D-penicillamine likewise brought about a subsidence of chronic arthritis (experimentally induced) in 3 out of 4 rabbits. A concomitant reduction in specific IgG antibodies against the experimental antigen (ovalbumin) was observed, but only when treatment with the drug was commenced prior to primary immunization.
[Fuller accounts of this work will appear in Stanworth et al. (1976) Secondly, we are delighted to see that his immunoglobulin profile showed the same degree of stability as our own. But I wonder whether we have arrived at opposite conclusions. Although patients with raised immunoglobulins, our 'collagenosis type', certainly reflect response to drug therapyas these patients improve clinically, there are marked changes in the levelswe find that the 'normal profile' patients (i.e. those with immunoglobulin levels within the 'normal' ranges established at the Protein Reference Unit, Sheffield) show little correlation between clinical activity and level. These patients seem to do very well on any therapy. On the other hand, although the collagenosis-type patients show a good correlation between levels and clinical activity, as a group they do not respond well to therapy.
Dr Stanworth: In answer to the second point, in 13 of the 15 patients we studied, we found that the IgG, for instance, remained within the normal range. I suppose it could be argued that we are dealing essentially with one of Dr Watkins' normal profile groups, but it seems rather unlikely. With IgM, 4 out of 15 decreased, but all stayed within the normal range throughout the whole study. Seven out of 15 had normal IgA throughout the study, 2 became normal during the study. It is well known, as Dr Swannell mentioned, that serum IgA levels are often raised initially in rheumatoid arthritis.
Turning to IgE, we have not looked at other conditions, such as SLE. Perhaps I should have quoted the duplicates, because we made duplicate analyses each time, and the variation in this assay is usually very small. We have applied it successfully to the study of hypogammaglobulinemic patients who have extremely low levels of IgE. We were taking the normal range as between 25 and 375 ml.
The important point to stress is that there is a significant increase in circulating IgE. I do not know what this increase means, but we are fairly confident that our data reflect such an increase. In most cases, admittedly, this is perhaps only moving to the top of the normal range; but it is the fact that there is an increase which is important.
The previous study, with which I think Dr Huskisson was involved, mainly dealt with falls in IgE levels over a rather shorter time period. Dr Watkins: We are mostly considering generalized immunoglobulin increase, not specific production of antibody.
Dr Stanworth has suggested that the rise in IgE titre may correlate with an immunological response to penicillamine. Would he elaborate on this ? Dr Stanworth: As far as antibody is concerned, we have tried, so far unsuccessfully, to demonstrate an effect of penicillamine on IgE antibody formation in rats. I should add that it was not given at an optimum time, which is relevant to Dr Huskisson's remarks. We wondered, in fact, whether we were not seeing some stimulatory effect on T cells, because we know that T cells are particularly involved in the synthesis of IgE. They are involved at an initial helper stage, and subsequently at a suppressor stage. We wondered whether penicillamine stimulates both of these T cell functions, in particular, because there is some evidence of thiols stimulating lymphocytes in vitro.
The penicillamine was administered to the rats at a time when we thought stimulation would be taking place, but there was no stimulation. If anything there was a slight depression in IgE production. We did not give the drug under conditions in which we might expect to see optimum effectfor instance, as a prolonged course of application. This would be well worth doing because it is easy to monitor IgE antibody production in rats. Dr A St J Dixon (Bath): Further to the point put by Dr Jellum about a trial of thiomalic acid in rheumatoid arthritis, I noticed that there is an asymmetric carbon atom present. We know that for penicillamine it is important to use the D-isomer and not the L-isomer. What about the thiomalic acidis it important to use one of the isomers, or the racemic mixture ? Dr Jellum: I cannot answer that because no one has investigated it, as far as I know. It is certainly an aspect which should be considered. The Dand L-forms ought to be made separately and tried separatelythat would probably be the best thing to do. Dr Stanworth: My colleague, Philip Johns, has pointed out that in our nonresponder there were normal serum immunoglobulin (IgG, IgA and IgM) levels. Dr D N Golding (Harlow): I was interested in Dr Stanworth's early rise in the titre of ANF, which shows the importance of measuring antinuclear factor before putting the patient on treatment if we want to be able to interpret a rise in antinuclear factor (or the existence of high ANF later on) with respect to breakthrough of drug dosage and side-effects. Was DNA binding measured in these patients? Dr Stanworth: Yes. Dr Felix-Davies: I think we had two positives at a fairly low level of binding, about 20%, before treatment. Dr Stanworth: I have some details which I could show afterwards. I certainly agree with the comments about antinuclear factor. Dr M I V Jayson (Bristol): When Paul Davies was with us he reported elevated IgE levels in patients on gold. This, of course, makes an interesting comparison, with reference to our earlier discussion. He was able to relate this elevation to the incidence ofside-effects from gold. Has the elevation of IgE levels on penicillamine been related either to toxic reactions or to possible benefit? Dr Felix-Davies: I thought that the eventual outcome showed that there was probably no relationship between rise in IgE and the susceptibility to side-effects on gold -was that not the eventual outcome? Dr Jayson: There was a relationship in that study. Some patients develop elevated IgE levels without side-effects. However, there is a higher incidence of side-effects in patients with high IgE levels.
Dr Stanworth: We are now carrying out a comparison of gold and penicillamine treatment and we will look for this. It will certainly be most interesting if there is a similar effect; but I was under the impression, in general, that there was not a high incidence in penicillamine-treated patients. Dr Felix-Davies: There have been two rashes. Dr F Wollheim (Malmd): Regarding the paper by Jellum et al. suggesting that Myocrisin might act not as a gold compound but as a sulphydryl agent, I want to mention that we have analysed the blood of 5 patients on weekly Myocrisin therapy for the content of plasma IgA-alantitrypsin complexes. We have previously shown disappearance of these normally occurring complexes to be a sensitive indicator of penicillamine effect in vivo (Wollheim F A, Jeppsson J 0 & Laurell C-B (1976) in: Penicillamine Research in Rheumatoid Disease. Ed. E Munthe. Merck, Sharp & Dohme, Norway; pp 152-160). However all 5 patients in the presence of a good clinical gold response had a normal concentration of the complexes. We can therefore conclude that Myocrisin does not prevent formation of this SS-linked protein complex and thus probably is not as good a sulphydryl agent as penicillamine. Dr H E Amos (Carshalton): A number of speakers have referred to hapten-carrier relationships in connection with the mechanism of adverse responses to penicillamine, but what is the hapten and what is the carrier? The known data could be explained by considering that the carrier is penicillamine and the hapten is part of the tissue macromolecule. The initiating stimulus for the immune response would be the foreign moiety of the complexes, i.e. penicillamine, and this would generate antibodies against the hapten. Antipenicillamine antibodies have been detected, and there are a number of reports indicating that autoantibodies are also produced. The lathyrogenic effect of penicillamine may be important in the formation of hapten-carrier complexes, particularly if they break loose from fixed sites and circulate in the blood. Dr Jaffe: It is a perfectly plausible theory, particularly in view of the lathyrogenic properties of the drug which could cause it to bind to collagen, denaturing it in the process. Dr Jayson once took me up on this because he felt that the different collagens would not react biochemically with the drug except for dermal collagen. Even that could be a good hapten source because there is plenty of skin. Beyond that, it is not possible to say anything other than that it is a plausible suggestion. In reply to Dr Jellum's point about the gold/penicillamine identity, he said more in his 10 minutes than I did when I spoke for 25 minutes on the subject recently.
I would like to suggest that there may be a much easier way to answer the question he raises than doing a controlled trial. We throw out the term 'controlled trial' rather freely, but it is quite difficult to do such trials. Gold and penicillamine share one thing in common; that is their striking effect on rheumatoid factor (RF) titre. I suggest that 3 or 4 patients, with a reasonably good titre, be given thiomalate in an open study. Their clinical changes would be of secondary importance, but careful monitoring of RF titres would be performed. A significant fall in RF titre induced by thiomalate after 4-6 months would be very provocative and merit a full clinical trial. In 1963 I had occasion to do almost the identical experiment using thioglucose, which is the moiety of Solganal, kindly prepared for me by the Schering Corporation. I gave 1 g a day for 4 months to one patient. Nothing happened clinically or to the RF titre, but that should not dissuade you from going ahead.
Dr J Glyn (London): I wonder whether that experiment has already been done in the sense that in the Empire Rheumatism Council gold trial, to which Dr Dixon has referred, the controls were on the thiomalate. Is that correct ? Dr A G S Hill (Stoke Mandeville): The controls were on a dose of Myocrisin which was onethousandth of the dose which was used in the 'treated' series, i.e. a course totalling I mg instead of 1000 mg.
Concluding Remarks by Dr A G S Hill (Stoke Mandeville)
The speakers have given their material with such clarity that it would be presumptuous to try to sum up. It gives me the opportunity, however, of saying a few things which are relevant, if not amounting to a formal summing up.
First, an impression which I have had for a long time about penicillamine has been reinforced by this meeting. It is that one does not do clinical trials and experiments with this agent, but has an affaire with it. I would not for a moment suggest that this in any way detracts from the scientifically critical approach that all of us have to it, but it is intriguing to observe its emotional effect. We could enlarge upon this by looking at the delightful programme cover depicting Pandora. Various other characteristics were recognized in speeches last night: she can be fickle, rewarding, even frustrating. This is why the compound is such an excellent centrepiece for a meeting like this and why it has produced such a feeling of community among the people who have dealt with it from all aspects. I wonder what Dr Walshe really thinks of the way rheumatologists have seized upon penicillamine. He introduced a wonderfully precise key which fitted the lock of a very rare disease. Rheumatologists have adopted it without any clear idea of how it works in their field, and have used it in one of the commonest diseases in the world. We have treated it as a sort of master key which will unlock a lot of doors, but we do not know which one it is unlocking.
